Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Cocrystal Pharma's shares outstanding for the quarter that ended in Mar. 2026 was 13.79 Mil.
Cocrystal Pharma's quarterly shares outstanding
increased
from Dec. 2025 (13.78 Mil) to Mar. 2026 (13.79 Mil).
It means Cocrystal Pharmaissued new shares from Dec. 2025 to Mar. 2026 .
Cocrystal Pharma's annual shares outstanding
increased
from Dec. 2024 (10.17 Mil) to Dec. 2025 (13.78 Mil).
It means Cocrystal Pharmaissued new shares from Dec. 2024 to Dec. 2025 .
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Cocrystal Pharma Shares Outstanding (EOP) Related Terms
Cocrystal Pharma Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for Cocrystal Pharma's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COCP vs OSRH, CVKD, LEXX: Shares Outstanding (EOP) Comparison
For the Biotechnology subindustry, Cocrystal Pharma's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cocrystal Pharma Shares Outstanding (EOP) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Cocrystal Pharma's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 13.79 Mil mean?
Cocrystal Pharma (COCP) has a Shares Outstanding (EOP) of 13.79 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Cocrystal Pharma and its competitors.
Is Cocrystal Pharma's Shares Outstanding (EOP) too high?
Cocrystal Pharma's current Shares Outstanding (EOP) is 13.79 Mil. Overall, Cocrystal Pharma has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cocrystal Pharma's Shares Outstanding (EOP) compare to OSRH and CVKD?
Cocrystal Pharma's Shares Outstanding (EOP) of 13.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Cocrystal Pharma and its competitors. Cocrystal Pharma's current Shares Outstanding (EOP) is 13.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cocrystal Pharma stock overvalued right now?
Cocrystal Pharma (COCP) has a current Shares Outstanding (EOP) of 13.79 Mil. The current Shares Outstanding (EOP) is 13.79 Mil. Cocrystal Pharma's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Cocrystal Pharma (COCP), the current Shares Outstanding (EOP) is 13.79 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
25GF Score
Get the complete analysis for COCP
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COCP has been successfully added to your 
